Breaking News
1 hour ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Recludix Pharma's oral STAT6 inhibitor REX-8756 matched biologic efficacy in preclinical atopic dermatitis models with a differentiated safety profile vs. JAK inhibitors.
Pharma Now Editorial Team

AstraZeneca's Imfinzi delivers survival gains in muscle-invasive bladder cancer, with perioperative use raising supply and QA coordination demands.
Pharma Now Editorial Team

Telix signs LOIs with EDAP and Profound to explore PSMA-PET imaging in HIFU and TULSA prostate cancer workflows, outside current approved indications.
Pharma Now Editorial Team

aTyr Pharma plans a June 2026 IND filing for an efzofitimod Phase 3 study in pulmonary sarcoidosis following FDA Type C meeting feedback on endpoint design.
Pharma Now Editorial Team
